Home | Meeting coverage | SABCS 2021

EBC Highlights

SABCS 2021

Hope Hugo, MD

Good data with further questions for future treatment...

KEYNOTE-522

SABCS 2021

Rebecca Dent, MD

The next standard for TNBC?!

Keynote-522

SABCS 2021

Nadia Harbeck, MD

Critical consideration of the study data is necessary

RXPONDER

SABCS 2021

Michael Untch, MD

Negative results with hope for translational projects

PALLAS

SABCS 2021

Michael Untch, MD

Re-evaluation confirms old data

KeyNOTE-522

SABCS 2021

Peter A. Fasching, MD

The risk-adapted decision for or against AI has to be...

TEXT, SOFT

SABCS 2021

Giuseppe Curigliano, MD

Benefit only related to chemotherapy?!

RxPONDER

SABCS 2021

Karen Gelmon, MD

Metformin shows no efficacy for most cancer patients

CCtG MA.32 (Metformin)

SABCS 2021

Karen Gelmon, MD

Leading the way for other ct-DNA trials

cTRAK TN

SABCS 2021

Andreas Schneeweiss, MD

Molecular-guided treatment is of value in combination...

BRE12-158

SABCS 2021

Alessandra Gennari, MD

Genomic signatures of DCIS

Breast Pre-Cancer Atlas

SABCS 2021

Rebecca Dent, MD

Solved and unsolved controversies of early breast...

RXPonder; CCtGMA.32 (Metformin)

SABCS 2021

Nadia Harbeck, MD

Hypothesis-generating study in the HER2-enriched...

KEYRICHED-1

SABCS 2021

Alessandra Gennari, MD

Metformin is not an anti-cancer drug

CCtGMA.32 (Metformin)

EBC Highlights: Multi-Language

SABCS 2021

Nadia Harbeck, MD

Kritische Betrachtung der Studiendaten notwendig

RXPONDER

SABCS 2021

Michael Untch, MD

Erneute Auswertung bestätigt alte Daten

KeyNOTE-522

SABCS 2021

Peter A. Fasching, MD

Muss die risiko-adaptierte Entscheidungsfindung bei AI...

TEXT, SOFT

SABCS 2021

Giuseppe Curigliano, MD

E’ solo effetto della chemioterapia?

RxPONDER

SABCS 2021

Alessandra Gennari, MD

"Signatures Genomiche " nel carcinoma duttale in situ

Breast Pre-Cancer Atlas

SABCS 2021

Andreas Schneeweiss, MD

Genomisch gesteuererte Therapie sinnvoll in Kombi mit...

Bre12-158

SABCS 2021

Nadia Harbeck, MD

Hypothesen-generierende Studie beim HER2-enriched...

KEYRICHED-1

SABCS 2021

Michael Untch, MD

Negative Ergebnisse, aber Hoffnung für translationale...

PALLAS

SABCS 2021

Alessandra Gennari, MD

La metformina non può essere considerata un farmaco...

CCtGMA.32 (Metformin)

EBC Discussions: SABCS 2021

SABCS 2021

S. Tolaney, K. Gelmon, N. Harbeck, H. Rugo, A. Schneeweiss, M. Untch

cTRAK TN: ctDNA monitoring not yet ready for primetime....

cTRAK TN

SABCS 2021

H. Rugo, K. Gelmon, S. Tolaney, N. Harbeck, A. Schneeweiss, M. Untch

KEYNOTE-522 confirms ICI benefit in the neoadjuvant...

Keynote-522; OlympiA

SABCS 2021

N. Harbeck, K. Gelmon, S. Tolaney, H. Rugo, M. Untch, A. Schneeweiss

RxPONDER: Benefit only for pre-menopausal patients?...

RxPONDER

EBC Discussions: Treatment Perspectives

SABCS 2021

P. A. Fasching, D. Lüftner, R. Dent, G. Curigliano, A. Schneeweiss

HR+ EBC: What about PALLAS/PENELOPE-B? What is the...

PALLAS; PENELOPE-B

SABCS 2021

G. Curigliano, A. Schneeweiss, R. Dent, P. A. Fasching, D. Lüftner

HER2+ EBC: Chemotherapy free regimens? Extended...

Destiny-Breast 03; DAISY; SUMMIT

SABCS 2021

R. Dent, A. Schneeweiss, G. Curigliano, P. A. Fasching, D. Lüftner

TNBC EBC: What is the new neoadjuvant standard...

Keynote-522

SABCS 2021

A. Schneeweiss, R. Dent, G. Curigliano, P. A. Fasching, D. Lüftner

MOLECULAR DIAGNOSTICS EBC: ctDNA for early detection of...

MBC Highlights

SABCS 2021

Andreas Schneeweiss, MD

Oral SERDs are efficient, but show high progression...

EMERALD

SABCS 2021

Sara Tolaney, MD

Activity of T-Dxd across all Her2-expressing breast...

DAISY

SABCS 2021

Véronique Diéras, MD

PFS improvement with fulvestrant in patients with...

Pada-1

SABCS 2021

Volkmar Müller, MD

Chekpoint inhibition in breast cancer

Nimbus; Keynote-355

SABCS 2021

Elzbieta Senkus-Konefka, MD

Elacestrant - less than we expected

EMERALD

SABCS 2021

Andreas Schneeweiss, MD

Switching with molecular progress improves PFS

Pada-1

SABCS 2021

Véronique Diéras, MD

Reconfirming effect of T-DXd in patients with brain...

Destiny-Breast03; DAISY

SBCS 2021

Sara Tolaney, MD

Dato-Dxd for metastatic TNBC

Tropion-PanTumor01

SABCS 2021

Elzbieta Senkus-Konefka, MD

Samuraciclib - new targeted therapy for luminal breast...

Samuraciclib Phase I

SABCS 2021

Sara Tolaney, MD

Immuntherapy for high tumor mutation burden in...

NIMBUS

SABCS 2021

Diana Lüftner, MD

IO + IO without resounding success in the mBC setting

Nimbus

SABCS 2021

Elzbieta Senkus-Konefka, MD

Dato-DXd new promising ADC

Tropion-PanTumor01

SABCS 2021

Michael Untch, MD

Effectiveness depending on PDL1 status

KeyNOTE-355

SABCS 2021

Elzbieta Senkus-Konefka, MD

T-Dxd is also active in patients with brain metastasis

Destiny-Breast03

SABCS 2021

Peter A. Fasching, MD

TDXd is very efficient in patients with brain...

DESTINY Breast-03

SABCS 2021

Peter A. Fasching

Oral SERDs for early setting and adjuvant therapy

EMERALD

SABCS 2021

Peter A. Fasching, MD

Pooled analyses shows OS benefit for most subgroups

MONALEESA 2, 3, 7

SABCS 2021

Peter A. Fasching, MD

Patients with BRCA2 don't show PFS benefit with CDK4/6i

MSK IMPACT

SABCS 2021

Peter A. Fasching, MD

Pioneering study of personalized medicine in advanced...

SAFIR02-Breast

SABCS 2021

Javier Cortes, MD

My highlights of 2021 in metastatic breast cancer

SABCS 2021

Carmen Criscitiello, MD

Amazing period for patients with refractory metastatic...

SABCS 2021

Barbara Pistilli, MD

Promising results for TNBC patients

Tropion-PanTumor01

SABCS 2021

Giuseppe Curigliano, MD

Very good news for endocrine resistant metastatic...

EMERALD

SABCS 2021

Karen Gelmon, MD

3 updates - 3 new standards of care

Keynote-522 Keynote-355 Destiny-Breast03

SABCS 2021

Javier Cortes, MD

Final results of the CPS score subgroup analyses show...

Keynote-355

SABCS 2021

Rebecca Dent, MD

Exciting novel therapies for metastatic TNBC

Keynote-355; Tropion-PanTumor01

SABCS 2021

Andreas Schneeweiss, MD

Best of the year: systemic therapy

SABCS 2021

Véronique Diéras, MD

Robust benefit of pembroluzimab in addition to...

KeyNOTE-522

ASH 2021

Carmen Criscitiello, MD

Imaging with mass cytometry can provide predictive...

NeoTRIPaPDL1

SABCS 2021

Volkmar Müller, MD

TROP2 - new target for improved chemotherapy

TROPION-PanTumor01; ASCENT

SABCS 2021

Andreas Schneeweiss, MD

Precision oncology is beneficial in certain mBC...

SAFIR02-Breast

SABCS 2021

Hope Rugo, MD

Which patients will benefit from Pembro in metastatic...

KEYNOT-355

SABCS 2021

Rebecca Dent, MD

More good news for TDXd

Destiny-Breast03; DAISY

MBC Highlights: Multi-Language

SABCS 2021

Carmen Criscitiello, MD

È un grande momento per i pazienti con tumore mammario...

Tropion-PanTumor01

SABCS 2021

Barbara Pistilli, MD

Risultati promettenti nel tumore al seno triplo...

Tropion-PanTumor01

SABCS 2021

Barbara Pistilli, MD

Résultats prometteurs dans le cancer du sein triple...

Tropion-PanTumor01

SABCS 2021

Giuseppe Curigliano, MD

Buone notizie per i tumori mammari endocrino resistenti

Emerald

SABCS 2021

Andreas Schneeweiss, MD

Best of the Year: Systemtherapie

SABCS 2021

Véronique Diéras, MD

Important benefice de l’ajout du pembrolizumab à la...

Keynote-522

SABCS 2021

Volkmar Müller, MD

Neues Target für optimierte Chemotherapie

Tropion-PanTumor01; Ascent

SABCS 2021

Carmen Criscitiello, MD

L’imaging mass cytometry può aiutare a predire...

NeoTRIPaPDL1

SABCS 2021

Elzbieta Senkus-Konefka, MD

Elacestrant – poniżej oczekiwań

Emerald

SABCS 2021

Andreas Schneeweiss, MD

Oraler Serd wirkt, aber hohe Rate an primärer Resistenz

Emerald

SABCS 2021

Véronique Diéras, MD

Amélioration de la survie sans progression par le...

Pada-1

SABCS 2021

Volkmar Müller, MD

Checkpoint-Inhibition beim Mammakarzinom

Nimbus; Keynote-355

SABCS 2021

Andreas Schneeweiss, MD

Umstellung bei molekularem Progress verlängert PFS

PADA-1

SABCS 2021

Elzbieta Senkus-Konefka, MD

Samuracyklib – nowe leczenie celowane w rakach...

Samuraciclib Phase I

SABCS 2021

Véronique Diéras, MD

Activité du T-DXd dans les metastases cérébrales

Destiny-Breast03

SABCS 2021

Andreas Schneeweiss, MD

Präzisionsonkologie funktioniert beim mBC

SAFIR02-BREAST

SABCS 2021

Diana Lüftner, MD

IO + IO ohne durchschlagenden Erfolg beim mBC

Nimbus

SABCS 2021

Elzbieta Senkus-Konefka, MD

Dato-DXd – nowy obiecujący koniugat przeciwciała i...

Tropion-PanTumor01

SABCS 2021

Michael Untch, MD

Wirksamkeit in Abhängigkeit von PDL1-Stautus

KeyNOTE-355

SABCS 2021

Elzbieta Senkus-Konefka, MD

T-Dxd aktywny również w przerzutach do mózgu

Destiny-Breast03

SABCS 2021

Peter A. Fasching, MD

TDXd zeigt große Wirksamkeit bei Hirnmetastasen

Destiny-Breast-03

SABCS 2021

Peter A. Fasching, MD

Werden orale SERDs die Therapie mit Fulvestrant in...

Emerald

SABCS 2021

Peter A. Fasching, MD

Gepoolte Analyse zeigt OS Vorteil für fast alle...

Monaleesa 2, 3, 7

SABCS 2021

Peter A. Fasching, MD

HER2 Patientinnen mit BRCA2 Mutation haben PFS Nachteil...

MSK Impact

SABCS 2021

Peter A. Fasching, MD

Wegweisende Daten für die personalisierte Medizin beim...

Safir02-Breast

SABCS 2021

Javier Cortes, MD

Mi retrospectiva del cáncer de mama metastático en 2021

SABCS 2021

Javier Cortes, MD

Resultados finales de los análisis de los subgrupos de...

Keynote-355

MBC Discussions: Treatment Perspectives

SABCS 2021

J. Cortes, D. Lüftner, C. Criscitiello, V. Dieras, F. Cardos, V. Müller

MBC HER2+: How can we manage the metastatic disease and...

SABCS 2021

C. Criscitiello, V. Müller, V. Dieras, J. Cortes, F. Cardoso, D. Lüftner

MBC HR+: What is the best option after a CDK4/6i...

SABCS 2021

Cardoso, V. Müller, C. Criscitiello, V. Dieras, J. Cortes, D. Lüftner

Integrating patients perspectives in metastatic breast...

SABCS 2021

V. Dieras, D. Lüftner, C. Criscitiello, F. Cardoso, J. Cortes, V. Müller

MBC TNBC: Molecular tumor characteristics define the...

MBC Discussions: SABCS 2021

SABCS 2021

M. Untch, V. Müller, B. Pistilli, A. Gennari, E. Senkus-Konefka

Are SERDs a future therapy for endocrine resistant...

EMERALD

SABCS 2021

V. Müller, A. Gennari, B. Pistilli, E. Senkus-Konefka, M. Untch

Treatment options for patients with metastatic TNBC

Keynote-355

SABCS 2021

M. Untch, E. Senkus-Konefka, A. Gennari, B. Pistilli, V. Müller

Therapy of brain metastasis – can T-DXd be the new SoC?

Destiny-Breast03

SABCS 2021

M. Untch, B. Pistilli, E. Senkus-Konefka, A. Gennari, V. Müller

New ADCs on the horizon for TNBC patients

TROPION-Tumor01

SABCS 2021

V. Müller, A. Gennari, B. Pistilli, E. Senkus-Konefka, M. Untch

Targeting rare mutations in breast cancer - is this the...

SUMMIT